LOGC241115C2000
- 0.00
- 0.000.00%
ContextLogic Newsroom
UBS Adjusts Price Target on LogicBio Therapeutics to $6.30 From $6.10, Maintains Neutral Rating
UBS Adjusts ContextLogic Price Target to $5 From $4.90, Maintains Neutral Rating
UBS Adjusts ContextLogic Price Target to $4.90 From $6.50, Maintains Neutral Rating
ContextLogic Analyst Ratings
Loop Capital Upgrades ContextLogic to Hold, Lowers Price Target to $4
ContextLogic Analyst Ratings
What 5 Analyst Ratings Have To Say About ContextLogic
Citigroup Maintains Sell on ContextLogic, Lowers Price Target to $5
ContextLogic Analyst Ratings
UBS Maintains Neutral on ContextLogic, Lowers Price Target to $6.5
Credit Suisse Adjusts ContextLogic's Price Target to $7 From $9, Keeps Outperform Rating
ContextLogic Analyst Ratings
Loop Capital Markets Reaffirms Their Sell Rating on ContextLogic (WISH)
Loop Capital Downgrades ContextLogic to Sell, Announces $7 Price Target
Credit Suisse Lifts ContextLogic's Price Target to $9 From $4.40, Keeps Outperform Rating
Credit Suisse Maintains Outperform on ContextLogic, Raises Price Target to $9
UBS Adjusts ContextLogic Price Target to $7.80 From $8.30, Maintains Neutral Rating
Credit Suisse Lowers ContextLogic's Price Target to $4.40 From $5.70, Keeps Outperform Rating
Credit Suisse Maintains Outperform on ContextLogic, Lowers Price Target to $4.4
Analysts Offer Insights on Consumer Goods Companies: Revolve Group (RVLV) and ContextLogic (WISH)